Metallothioneins and neurodegenerative diseases

被引：38

作者：

Hozumi, I

Asanuma, M

Yamada, M

Uchida, Y

机构：

[1] Gifu Univ, Grad Sch Med, Dept Neurol & Geriatr, Gifu 5011194, Japan

[2] Okayama Univ, Grad Sch Med & Dent, Dept Brain Sci, Okayama 7008558, Japan

[3] Niigata Univ, Dept Pathol, Brain Res Inst, Niigata 9518585, Japan

[4] Tokyo Metropolitan Inst Gerontol, Gene Express Res Grp, Itabashi Ku, Tokyo 1730015, Japan

来源：

JOURNAL OF HEALTH SCIENCE | 2004年 / 50卷 / 04期

关键词：

metallothionein; growth inhibitory factor; neurodegenerative disease; Alzheimer's disease; amyotrophic; lateral sclerosis;

D O I：

10.1248/jhs.50.323

中图分类号：

R99 [毒物学（毒理学）];

学科分类号：

100405 ;

摘要：

A symposium on the clinical aspects of metallothioneins (MTs) in neurodegenerative diseases was held at the 2003 Society of Metallothionein Meeting in Gifu, Japan. The objectives of the symposium were to review and speculate on the potential roles of MTs, especially MT-3 in neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and spinocerebellar degeneration (SCD). Dr. Uchida discussed the controversial problem regarding the expression of MT-3 in AD brains. Dr. Asanuma addressed the function of MTs in the progression of PD and Dr. Hozumi described the therapeutic potential of MTs for ALS, while Dr. Yamada provided immunohistochemical findings of MT-3 in SCD for the first time. Although there are still controversial problems on MTs, this review provides proof that MTs are promising potential therapeutic targets for therapy for some neurodegenerative diseases.

引用

页码：323 / 331

页数：9

共 52 条

[1] Regulation of metallothionein-III (GIF) mRNA in the brain of patients with Alzheimer disease is not impaired [J].